

Correction: Oncopeptides presents new data at the European Haematology Association meeting

Updated information

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that new scientific data on melflufen has been accepted at the European Hematology Association meeting (EHA) in Frankfurt, Germany on June 9, 2023. The data includes one clinical abstract on final efficacy and safety data from the phase 1 /2 ANCHOR study, and one preclinical abstract on melflufen showing efficacy in association with decreased and mutated TP53 activity and enrichment of genes involved in DNA damage repair.

The abstracts are available on the following link (search with the abstract code): [EHA Open Access Library](#).

ANCHOR is a phase 1/2 open label multicenter study evaluating the safety and efficacy of melflufen plus dexamethasone in combination with either daratumumab or bortezomib in patients with relapsed refractory multiple myeloma (RRMM). The study started in April 2018 and was prematurely closed in February 2022 with 56 patients enrolled. The final analysis continues to support the previously reported efficacy and safety data that subsequently led to the initiation of the confirmatory phase 3 LIGHTHOUSE trial. Data from the LIGHTHOUSE study was recently presented at the European Myeloma Network meeting.

“The triplet combination of melflufen plus dexamethasone and daratumumab or bortezomib, showed encouraging clinical activity in patients with RRMM who previously have received 1-4 prior lines of therapy,” says Enrique M. Ocio, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain. “The triplet combinations with melflufen showed a predictable and manageable safety profile, which are important factors for patients in later lines of therapies.”

Scientific abstract	First author	Abstract type	Abstract code
ANCHOR (op-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma—final efficacy and safety results.	Prof. Enrique M. Ocio, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain.	Poster presentation	P876
Sensitivity of multiple myeloma to melflufen associates with decreased P53 activity and enrichment of DNA damage repair pathway genes	Mr. Juho Miettinen, Institute for Molecular Medicine Finland (FiMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland	Publication only	PB2071

For more information, please contact:

Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)

E-mail: rolf.gulliksen@oncopeptides.com

Cell phone: + 46 70 262 96 28

About Oncopeptides

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.

Attachments

[Oncopeptides presents new data at the European Haematology Association meeting](#)